ARTICLE | Company News
Hyperion, Valeant Pharmaceuticals deal
June 10, 2013 7:00 AM UTC
Hyperion completed the acquisition of worldwide rights to Buphenyl sodium phenylbutyrate from Valeant's Ucyclyd Pharma Inc. subsidiary. The exercise price was $19 million. The subsidiary exercised its...